Publisher
Japanese Society on Thrombosis and Hemostasis
Reference25 articles.
1. 1) 「血友病患者のQOLに関する研究」令和2年度調査報告書 2021［Available from: https://www.ims.u-tokyo.ac.jp/jointsurgery/pdf/R2.pdf］2021年10月23日参照．
2. 2) 血液凝固異常症全国調査 令和2年度報告書 2021［Available from: https://api-net.jfap.or.jp/image/data/blood/r02_research/r02_research.pdf］2021年10月23日参照．
3. 3) Oldenburg J, Mahlangu JN, Kim B, et al.: Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 377: 809–818, 2017.
4. 4) Young G, Liesner R, Chang T, et al.: A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134: 2127–2138, 2019.
5. 5) Oldenburg J, Mahlangu JN, Bujan W, et al.: The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 25: 33–44, 2019.